Please note: The information displayed on this page might be outdated.
Tarveda Therapeutics: Tarveda Therapeutics, Inc. is discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors. PEN-221 is a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors. PEN-221 is highly selective for SSTR2 and is designed to rapidly penetrate deep into solid tumors where it accumulates and releases its potent DM1 payload over time within the tumor cells. Tarveda is also advancing its HSP90 binding drug conjugate platform with lead drug candidate PEN-866, which selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38. The safety and efficacy of PEN-866 in patients with cancer is currently being evaluated in a clinical trial. Tarveda’s strategy includes developing its own proprietary miniature drug conjugates as well as applying its miniature drug conjugate platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators.
US - New England
Phase l or ll
134 Coolidge Ave
Watertown, MA 02472
Watertown, MA 02472
Company Participants at Spring Private Company Showcase
Tarveda Therapeutics, CEO
Brian Roberts is President and Chief Executive Officer at Tarveda Therapeutics. He joined Tarveda as Chief Financial Officer in January 2018. Brian has nearly 25 years of finance, capital markets and operations experience spanning the lifesciences, medtech and media industries with a proven track record of delivering positive results and driving shareholder value. Mr. Roberts served as Chief Financial and Operating Officer at Avedro, Inc., a privately held biotechnology company leading the organization through FDA approval, manufacturing readiness and commercial launch of its lead combination drug and medical device product. Previously, he served as Chief Financial Officer at Insulet Corporation, (NASDAQ: PODD) a leader in tubeless insulin pump technology. During his tenure, Insulet grew rapidly to nearly $300 million in revenue with a valuation of over $2 billion. Prior to Insulet, Brian served as CFO for Jingle Networks, acquired by Marchex, Inc., and as CFO for Digitas, (NASDAQ: DTAS) a leading digital marketing and media services firm acquired for $1.3 billion by Publicis Groupe. Brian has also held finance positions at Idiom Technologies, Inc., the Monitor Group and as an auditor with Ernst & Young LLP. Brian currently serves as Director and Audit Chairman for ViewRay, Inc., (NASDAQ:VRAY), a leader in MRI-guided radiation therapy, and as Director and Audit Chairman for Valeritas Holdings, Inc. (NASDAQ:VLRX), the maker of V-Go®, a daily insulin delivery device for people living with diabetes. Mr. Roberts holds a Bachelor of Science in Accounting and Finance from Boston College and is a Certified Public Accountant.